Literature DB >> 7843419

Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C).

P Engels1, M Sullivan, T Müller, H Lübbert.   

Abstract

We have recently reported increased survival of dopaminergic substantia nigra neurons by inhibition of phosphodiesterase type IV enzymes. As a first step to unravel the involvement of PDE IV subtypes in this process, we isolated phosphodiesterase type IV cDNAs from human substantia nigra. One isolated partial cDNA clone was most homologous to the partially cloned rat and human PDE IV-C isogene. Distribution analysis revealed that the enzyme is expressed in various tissues but not in cells of the immune system. Isolation of the full-length human PDE IV-C isogene cDNA and expression in a PDE-deficient yeast strain resulted in functional complementation of the yeast heat shock response. Inhibition of the enzymatic activity by rolipram characterized this enzyme as a typical type IV phosphodiesterase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7843419     DOI: 10.1016/0014-5793(94)01460-i

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

Review 1.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

Review 3.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

4.  CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.

Authors:  Alexandre Trifilieff; Thomas H Keller; Neil J Press; Trevor Howe; Peter Gedeck; David Beer; Christoph Walker
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 5.  A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity.

Authors:  Didem Demirbas; Ozge Ceyhan; Arlene R Wyman; Charles S Hoffman
Journal:  Handb Exp Pharmacol       Date:  2011

6.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.

Authors:  S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

7.  Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

Authors:  C D Manning; M Burman; S B Christensen; L B Cieslinski; D M Essayan; M Grous; T J Torphy; M S Barnette
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

8.  Acute hypoxia modifies cAMP levels induced by inhibitors of phosphodiesterase-4 in rat carotid bodies, carotid arteries and superior cervical ganglia.

Authors:  Ana R Nunes; Joana R Batuca; Emília C Monteiro
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

9.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.